Month: April 2021

PARIS, April 21, 2021 (GLOBE NEWSWIRE) — Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC), a biopharmaceutical company specializing in developing a new drug class that directly targets the brain to treat difficult-to-treat and resistant hypertension and heart failure, will present top-line results from its QUORUM study of firibastat in heart failure post myocardial infarction at the European Society of Cardiology (ESC) meeting in August 2021. These results will also be published in a peer-review journal. QUORUM (QUantum Genomics QCG001 Or Ramipril after acUte Myocardial infarction to prevent left ventricular dysfunction) is a multi-center, multinational, randomized, double- blind, active-controlled trial with three parallel groups (firibastat 100 mg BID, firibastat 500 mg BID and ramipril 5 mg BID) in subjects...

VANCOUVER, British Columbia, April 21, 2021 (GLOBE NEWSWIRE) — VALOREM RESOURCES INC. (the “Company” or “Valorem”) (CSE: VALU) (Frankfurt: 1XW1). Further to the Company’s announcement on April 19, 2021 regarding the receipt of exploration permits for its Wing Pond (Shear) Gold Property, the Company is pleased to report that it will be commencing field exploration work shortly. Initial work will consist of geological mapping, prospecting and a preliminary till-sampling program, commissioned through Overburden Drilling Management of Nepean, Ontario. Exploration will commence this week in preparation for an inaugural drilling campaign later in the year. Mr. Tony Louie, CEO of the Company commented, “We are very excited to begin working in the Gander Gold camp. We are fully funded to compete this planned exploration campaign and...

LONDON and RALEIGH, N.C., April 21, 2021 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its financial results for the three months ended March 31, 2021 on Thursday, April 29, 2021 and host an investment community conference call at 9:00 a.m. EDT / 2:00 p.m. BST to discuss these financial results and provide a corporate update. To participate, please dial one of the following numbers and reference conference ID 7429971:+1-888-317-6003 for callers in the United States +1-412-317-6061 for international callersA live webcast will be available on the Events and Presentations link on the Investors page of the Company’s website, www.veronapharma.com, and the audio replay will be available for 90 days. For...

KN invites shareholders, investors, analysts and other stakeholders to join its investor conference webinar scheduled on the April 30th of 2021 at 9.00 am (EET). The presentation will be held in English. The webinar will be hosted by KN Chief Executive Officer Darius Šilenskis and Chief Financial Officer Jonas Lenkšas who will introduce the performance and unaudited financial results of KN for the three months of 2021. After the presentation investors are welcome to ask questions. Due to limited webinar time, we encourage participants to send their questions before the webinar until July 28th to emilija.ivanauskaite@nasdaq.com How to join the webinar?To join the webinar, please register via following link: https://register.gotowebinar.com/register/7211612518603224845 You will be provided with the webinar link and instructions how to join...

Š.m. balandžio 30 d. 9.00 val. KN kviečia akcininkus, investuotojus, analitikus ir visus besidominčius į 2021 metų trijų mėnesių neaudituotų finansinių rezultatų pristatymą internetiniame seminare (angl. „webinar“), kuris vyks anglų kalba. Bendrovės 2021 metų trijų mėnesių neaudituotus finansinius rezultatus komentuos ir po prezentacijos į dalyvių klausimus atsakys KN Generalinis direktorius Darius Šilenskis ir Finansų direktorius Jonas Lenkšas. Dėl riboto seminarui skirto laiko maloniai prašome atsiųsti klausimus iš anksto iki 2021 m. balandžio 28 dienos el. paštu: emilija.ivanauskaite@nasdaq.com Kaip prisijungti prie internetinio seminaro? Visus norinčius dalyvauti internetiniame seminare, prašome registruotis aktyvuojant šią nuorodą: https://register.gotowebinar.com/register/7211612518603224845 Jums bus išsiųsta nuoroda prisijungti...

Issuer: Scatec ASA Ex. date: 21 April 2021 Dividend amount: 1.09 Announced currency: NOK This information is published in accordance with the requirements of the Continuing Obligations. For further information, please contact: Ingrid Aarsnes, VP Communication & IR,email: ir@scatecsolar.com   About Scatec ASA:Scatec is a leading renewable power producer, delivering affordable and clean energy worldwide. As a long- term player, Scatec develops, builds, owns and operates solar, wind and hydro power plants and storage solutions. In the first half of 2021, Scatec will have a total of 3.3 GW in operation on four continents and more than 500 employees. The company is targeting 15 GW capacity in operation or under construction by the end of 2025. Scatec is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange under the ticker...

Amsterdam, 21 April 2021 – Heineken Holding N.V. (EURONEXT: HEIO; OTCQX: HKHHY) publishes its trading update today for the first quarter of 2021.  KEY HIGHLIGHTSBeer volume stable organically Heineken® volume growth accelerated +12.1% Premium volume outperformed growing in the low-teens Deployment of EverGreen growth strategy on trackHeineken Holding N.V. engages in no activities other than its participating interest in Heineken N.V. and the management or supervision of and provision of services to that company.  FIRST QUARTER VOLUMEBeer volume1 2(in mhl or %) 1Q21 Organic growth 1Q20Consolidated beer volume 50.3  0.0  % 51.6 Heineken® volume1 (in mhl or %)1Q21 Organic growthHeineken N.V. 10.5  12.1  %1 Refer to the Definitions section for an explanation of organic growth and volume metrics.2 2021 volume reflects...

The board of directors of IDEX Biometrics ASA resolved on 20 April 2021 to issue 2,750,000 incentive subscription rights to an employee in the IDEX group. The grant was made under the company’s 2020 incentive subscription rights plan as resolved at the annual general meeting on 15 May 2020. The exercise price of the subscription rights is NOK 2.71 per share. The subscription rights vest by 25% per year over four years and expire on 15 May 2025. Following the grant there are 59,782,259 subscription rights outstanding in IDEX. For further information contact:Marianne Bøe, Investor RelationsE-mail: marianne.boe@idexbiometrics.comTel: + 47 9180 0186 About IDEX BiometricsIDEX Biometrics ASA (OSE: IDEX and Nasdaq: IDBA) is a leading provider of fingerprint identification technologies offering simple, secure, and personal touch-free authentication...

Oslo, Norway – 21 April 2021 – IDEX Biometrics ASA, a leading provider of advanced fingerprint identification and authentication solutions, has appointed James A. Simms as Chief Financial Officer with effect from 26 April 2021.     Mr. Simms is an accomplished executive, with extensive experience with publicly-listed companies across high technology. Since 2008, he has served as Chief Financial Officer and a member of the Board of Directors of Vicor Corporation (Nasdaq: VICR), for which he played a key role in repositioning the company strategically and organizationally, leading to an order of magnitude expansion of market capitalization. Prior to joining Vicor Corporation, Mr. Simms was an investment banker for two decades, most recently with Needham & Company, Inc.     Mr. Simms holds an MBA from the University of Pennsylvania...

  The board of directors of IDEX Biometrics ASA resolved the 2020 annual report on 20 April 2021. The financial statements are consistent with the preliminary report disclosed on 25 February 2021. The board does not propose a dividend. The 2020 annual report is enclosed in pdf file and is available at www.idexbiometrics.com (http://www.idexbiometrics.com). IDEX Biometrics ASA Annual report 2020: Idex Biometrics Annual report 2020 The board resolved to call the annual general meeting on 12 May 2021. Information concerning the annual general meeting will be published later. During 2020 IDEX made good progress transitioning from research and development to commercial activities. Even with the extraordinary challenges created by COVID-19 on business and society, the team was able to remain focused and execute on the 2020 business plan. Throughout...